Dr. Rocha Lima is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Wake Forest Baptist Medical Center
Division of Hematology and Oncology
Winston Salem, NC 27157Phone+1 336-713-5440Fax+1 336-713-5445
Education & Training
- Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 1995 - 1997
- Federal University of Bahia Faculty of MedicineClass of 1989
Certifications & Licensure
- FL State Medical License 2002 - 2026
- NC State Medical License 2017 - 2025
- SC State Medical License 2015 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 64 citations5-fluorouracil-induced coronary vasospasm.Laura Shoemaker, Umesh K. Arora, Caio Max S. Rocha Lima
Cancer Control. 2004-01-01 - 348 citationsA phase I dose-escalation trial of 2-deoxy- d -glucose alone or combined with docetaxel in patients with advanced solid tumorsLuis E. Raez, Kyriakos P. Papadopoulos, A. Ricart, E. Gabriella Chiorean, Robert S. DiPaola
Cancer Chemotherapy and Pharmacology. 2013-02-01 - 129 citationsPhase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard TherapyLeonard B. Saltz, Lee S. Rosen, John L. Marshall, Robert Belt, Herbert Hurwitz
Journal of Clinical Oncology. 2007-10-20
Lectures
- A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of p...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR).2019 ASCO Annual Meeting - 6/1/2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: